Abstract: S63845 is a highly specific myeloid leukemia-1 (MCL-1) inhibitor and BH3-mimetic that has emerged as a promising agent in cancer therapy, particularly in the context of combination therapeutics and resistance reversal. Overexpression of anti-apoptotic proteins like MCL-1 is a key mechanism by which cancer cells, including those in myelodysplastic syndromes (MDS), evade apoptosis and develop resistance to selective BCL-2 inhibitors such as venetoclax. S63845 effectively targets this bypass mechanism, demonstrating tolerability and efficacy across diverse cancer models. This review synthesizes current literature on S63845, detailing its pharmacological activity, molecular mechanism, and future potential in combination regimens to overcome apoptotic resistance.
1. Introduction
The evasion of apoptosis is a central hallmark of cancer, often driven by the dysregulation of the BCL-2 family of proteins [1]. The BCL-2 family includes anti-apoptotic proteins (such as BCL-2, BCL-XL, and MCL-1) that sequester pro-apoptotic members to prevent mitochondrial outer membrane permeabilization (MOMP) and subsequent cell death [1][2]. To exploit this vulnerability in cancer cells, BH3-mimetics have been developed to mimic the action of pro-apoptotic BH3-only proteins [1]. While BCL-2 selective inhibitors like venetoclax have shown significant clinical success, acquired resistance frequently emerges. A clinically relevant mechanism for this resistance is the upregulation of the MCL-1 protein, which creates a bypass pathway for tumor survival [2]. S63845, developed by Servier, is a potent and highly specific MCL-1 inhibitor designed to address this clinical challenge and reverse resistance in various malignancies [1][2].
2. Pharmacological Activity
S63845 has proven to be tolerable and effective in diverse cancer models [1]. In the context of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), S63845 is recognized as a targeted molecule with significant potential to break drug resistance [2]. When cancer cells are treated with BCL-2 inhibitors, they often form a specific bypass by significantly increasing the expression of the MCL-1 gene, leading to prolonged survival of the malignant cells [2]. S63845 exhibits potent pharmacological activity by specifically neutralizing this MCL-1-mediated resistance. It is currently undergoing trials and is proving to be effective and safe in multiple cancer types, paving the way for advanced lines of treatment for BH3 mimetic-resistant diseases [1][2].
3. Molecular Mechanism of Action
S63845 functions as a BH3-mimetic, specifically designed to mimic the interaction of BH3-only proteins with anti-apoptotic multidomain proteins [1]. The primary target of S63845 is MCL-1. Normally, MCL-1 promotes tumor survival by hetero-oligomerizing with and neutralizing pro-apoptotic BCL-2 family members such as BIM, BAK, NOXA, PUMA, or BID [2]. By binding to the canonical hydrophobic BH3-binding groove of MCL-1, S63845 competitively displaces these pro-apoptotic proteins [1]. This release allows the pro-apoptotic effectors (like BAX and BAK) to oligomerize and form pores in the mitochondrial membrane, thereby restoring the intrinsic apoptotic pathway and driving the cancer cell toward MOMP and subsequent death [1][2].
4. Structure-Activity Relationship (SAR)
The structure-activity relationship of BH3-mimetics like S63845 is centered on their ability to bind the specific hydrophobic groove of anti-apoptotic proteins [1]. S63845 was developed to overcome the limitations of earlier, less specific inhibitors. It demonstrates the greatest specificity for MCL-1 over other anti-apoptotic family members, namely BCL-2 and BCL-XL [1]. This high selectivity is crucial, as MCL-1 possesses a different structure compared to BCL-2 and BCL-XL—such as the absence of the BH4 domain and the presence of unusual amino acid residues in the BH3 domain. This structural divergence requires a highly tailored molecular fit, which S63845 achieves, allowing for effective inhibition without unwanted off-target binding to other BCL-2 family members [2].
5. Current Limitations
Despite its promise, the clinical application of S63845 faces significant challenges. A major limitation is the potential for on-target toxicity; MCL-1 is crucial for the survival of vital healthy cells, including cardiomyocytes and neurons [2]. Consequently, the systemic inhibition of MCL-1 could be dangerous and problematic in a clinical setting [2]. Furthermore, the apoptotic landscape in cancer is highly dynamic. Cancer cells exhibit single-cell heterogeneity and can rapidly shift their apoptotic thresholds in response to signaling changes, potentially leading to new forms of acquired resistance even when MCL-1 is successfully inhibited [1].
6. Future Perspectives
The future of S63845 lies heavily in combination therapeutics. Because tumors often rely on a combination of anti-apoptotic proteins to survive, using S63845 alongside other targeted agents is a rational strategy to prevent bypass resistance [1]. For instance, combining MCL-1 inhibitors with BCL-2 inhibitors (like venetoclax), hypomethylating agents (HMAs), or other resistance-breaking molecules (such as chidamide or arsenic trioxide) holds great potential for treating refractory diseases like MDS [2]. Additionally, utilizing predictive tools like dynamic BH3-profiling and assessing bone marrow cytoarchitecture could help clinicians identify which patients are most likely to benefit from S63845-based combination therapies, thereby personalizing treatment and minimizing adverse effects [1][2].
7. References
